ACQUIRED · 2024
Who Acquired Revance Therapeutics, Inc.?
Crown Laboratories, Inc. · $924.0M
The acquisition
Revance Therapeutics, Inc. was acquired by Crown Laboratories, Inc. in 2024 for $924.0M. at 3.70× revenue.
Revance Therapeutics, Inc. at time of acquisition
Revenue
$251.2M
Deal value
$924.0M
Similar medical devices acquisitions
- Owen Mumford Holdings · acquired by Embecta in 2026 · $201.0M
- Acera Surgical · acquired by Solventum in 2025 · $725.0M
- Alydia Health (Organon JADA System) · acquired by Laborie Medical Technologies in 2025 · $440.0M
- B Medical Systems (Azenta) · acquired by THELEMA S.A. R.L. in 2025 · $63.0M
- BIOTRONIK Vascular Intervention Business · acquired by Teleflex, Inc. in 2025 · $875.9M
Run a valuation for a similar medical devices business
Three fields, instant range, backed by 25,592 real M&A transactions including this one.
Open the medical devices calculator →More on medical devices valuations
- Medical Devices valuation calculator· head-term variant
- Medical Devices median multiples· real-deal benchmarks
- How to value a medical devices· long-form guide
Sourced from Press releases. Full deal page.
Citation: ExitValue.ai. (2024). Revance Therapeutics, Inc. acquired by Crown Laboratories, Inc.. https://exitvalue.ai/acquired/revance-therapeutics-inc